Pitavastatin: focus on safety and drug interactions

Cover Page

Cite item

Full Text

Abstract

Pitavastatin is a drug from the group of HMG-CoA reductase inhibitors, which has good lipid-lowering efficacy and has no significant effect on the risk of diabetes mellitus. This drug is non significantly metabolized by the P450 cytochrome system, which minimizes the risk of possible drug-drug interactions. Peptide organic anionic transporter inhibitors also may affect the efficacy and safety of the drug. This review summarizes the data on the problems of drug interactions of pitavastatin.

About the authors

Larisa O. Minushkina

Central State Medical Academy of the Administrative Department of the President of the Russian Federation

Author for correspondence.
Email: minushkina@mail.ru
ORCID iD: 0000-0002-4203-3586

D. Sci. (Med.)

Russian Federation, Moscow

Dmitry A. Zateyshchikov

Central State Medical Academy of the Administrative Department of the President of the Russian Federationa; City Clinical Hospital №51

Email: minushkina@mail.ru
ORCID iD: 0000-0001-7065-2045

D. Sci. (Med.), Prof.

Russian Federation, Moscow; Moscow

References

  1. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140–205.
  2. Ming EE, Davidson MH, Gandhi SK, et al. Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases. J Clin Lipidol 2008; 2 (6): 453–63.
  3. Masana L. Pitavastatin in cardiometabolic disease: therapeutic profile. Cardiovasc Diabetol 2013, 12 (Suppl. 1): S2.
  4. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005; 59 (2): 239–52.
  5. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica 2003; 33 (1): 27–41.
  6. Kajinami K, Takekoshi N, Saito Y. Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2003; 21 (3): 199–215.
  7. Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl 2011; 12 (3): 285–8.
  8. Chamberlin KW, Baker WL. Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients. Clin Interv Aging 2015; 10: 733–40.
  9. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009; 54 (4): 293–302.
  10. Taguchi I, Iimuro S, Iwata H, et al. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation 2018; 137 (19): 1997–2009.
  11. Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J 2017; 38 (29): 2264–76.
  12. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Exp Opin Pharmacother 2010; 11 (5): 817–28.
  13. Gosho M, Tanahashi M, Hounslow N, Teramoto T. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data. Int J Clin Pharmacol Ther 2015; 53 (8): 635–46.
  14. Fujino H, Yamada I, Shimada S, et al. Interaction between fibrates and statins – metabolic interactions with gemfibrozil. Drug Metabol Drug Interact 2003; 19 (3): 161–76.
  15. Fujino H, Shimada S, Yamada I, et al. Studies on the interaction between fibrates and statins using human hepatic microsomes. Arzneimittelforschung 2003; 53 (10): 701–7.
  16. Lee HW, Kang WY, Jung W, et al. Evaluation of the Pharmacokinetic Drug-Drug Interaction between Micronized Fenofibrate and Pitavastatin in Healthy Volunteers. Pharmaceutics 2020; 12 (9).
  17. Alam K, Pahwa S, Wang X, et al. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions. Mol Pharmaceut 2016; 13 (3): 839–51.
  18. Fujino H, Nakai D, Nakagomi R, et al. Metabolic stability and uptake by human hepatocytes of pitavastatin, a new inhibitor of HMG-CoA reductase. Arzneimittelforschung 2004; 54 (7): 382–8.
  19. Hu M, Mak VW, Yin OQ, et al. Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin. Drug Metab Pharmacokinet 2013; 28 (2): 104–8.
  20. Nakagawa S, Gosho M, Inazu Y, Hounslow N. Pitavastatin Concentrations Are Not Increased by CYP3A4 Inhibitor Itraconazole in Healthy Subjects. Clin Pharmacol Drug Dev 2013; 2 (2): 195–200.
  21. Sakaeda T, Fujino H, Komoto C, et al. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res 2006; 23 (3): 506–12.
  22. Wang YC, Hsieh TC, Chou CL, et al. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Medicine (Baltimore) 2016; 95 (2): 2487.
  23. Patel M, Kothari C. Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1138: 121962.
  24. Xu C, Fang D, Chen X, et al. Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs. Eur J Pharmacol 2015; 762: 364–71.
  25. Inagaki Y, Hunt T, Arana B, et al. Drug-drug interaction study to assess the effects of multiple-dose pitavastatin on steady-state warfarin in healthy adult volunteers. J Clin Pharmacol 2011; 51 (9): 1302–9.
  26. Yu CY, Campbell SE, Zhu B, et al. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin 2012; 28 (2): 187–94.
  27. Kim SJ, Yoshikado T, Ieiri I, et al. Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. Drug Metab Dispos 2016; 44 (10): 1622–32.
  28. Yu CY, Campbell SE, Sponseller CA, et al. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Investig 2014; 34 (7): 475–82.
  29. Morgan RE, Campbell SE, Suehira K, et al. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr 2012; 60 (2): 158–64.
  30. Trueck C, Hsin CH, Scherf-Clavel O, et al. A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin. Clin Pharmacol Ther 2019; 106 (6): 1398–07.
  31. Ahlström B, Frithiof R, Hultström M, et al. The swedish covid-19 intensive care cohort: risk factors of icu admission and icu mortality. Acta Anaesthesiol Scand 2021.
  32. Scheen AJ. Statins and clinical outcomes with COVID-19: Meta-analyses of observational studies. Diabetes Metab 2020; 47 (6): 101220.
  33. Reiner Ž, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 2020; 16 (3): 490–6.
  34. Baby K, Maity S, Mehta CH, et al. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An in silico drug repurposing for COVID-19. F1000Res 2020; 9: 1166.
  35. DeFilippi C, Toribio M, Wong LP, et al. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis 2020; 222 (6): 929–39.

Copyright (c) 2021 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies